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Breast cancer is the most commonly occurring cancer among women. Metastasis of 
primary breast cancer tumors is the main cause of death related to the disease. Growing 
tumor cells require an adequate blood supply, and have an intrinsic ability to attract new 
blood vessels via a process called angiogenesis. Extracellular nucleosides are important to 
the growth of various cancers, as well as endothelial function and blood flow regulation. 
One factor secreted from breast cancer cells is nucleoside diphosphate kinase (NDPK), 
which functions to promote cell migration, growth, and tumor-mediated angiogenesis. 
Understanding the role of NDPK is important because identifying nucleoside function 
could lead to the prevention of metastasis development. The detection of NDPK activity in 
serum samples suggests that this may be one potential source for elevated ATP levels 
involved in purinergic mechanisms. The assay developed for the detection of NDPK 
utilizes the enzyme's transphosphorylation activity to generate ATP, which can be detected 













Primary breast tumors are thought to suppress the growth of their subclinical secondary 
metastases [1]. Breast tumor growth is not continuous, and tumor cells can migrate to other 
sites in the body before they are capable of forming aggressive disease and thus remain 
dormant [2]. Dying from breast cancer is exclusively a function of metastasis [3].  Those 
whose breast cancer metastasizes have only a 9% chance of living an additional 10 years, 
compared to a 56% survival rate for women with a reoccurrence isolated to the breast [4]. 
Cancer tumor survival requires an adequate supply of blood and nutrients. Growing tumor 
cells have an intrinsic ability to promote angiogenesis and attract new blood vessels, a 
hallmark of cancer [5]. What activates dormant cells at metastatic sites to move from a 
non-dividing state to aggressively growing is not known [6]. Tumor angiogenesis is the 
growth into a developing tumor of new capillary blood vessels. Anti-angiogenic 
compounds are secreted by primary tumors; and as suggested already, dormant metastases 
may be controlled by the primary tumor [7]. Some treatment success has been 
demonstrated with monoclonal antibodies to the angiogenic stimulator vascular endothelial 
growth factor (VEGF) and epidermal growth factor receptors. NDPK transphosphorylation 
activity is suspected to aid in tumor metastasis and survival, it is a potential target for use 
as a breast cancer biomarker. The ATP product which results from its activity can be 
targeted in a luciferin-luciferase activity assay, which once optimized should be able to 







Mouse model for human breast cancer and subsequent drug treatment 
A luciferase-tagged cell line,4T1-Luc2, was used. 4T1-Luc2 cells were cultured in RPMI 
1640 media supplemented with 10% fetal bovine serum at 37°C in 5% CO2. Cells were 
harvested with 0.05% trypsin and resuspended with 50:50 (v/v) with Matrigel (Sigma, MO) 
where 100ul of 1x105 cells were injected orthotopically into six-week old  female BALB/C 
mice at the abdominal mammary fat pad site. An in-vivo imaging system (IVIS) machine 
(Perkin Elmer, Santa Clara, CA) was used to gather image data and track growth and 
metastasis of primary tumors. In order for the IVIS to detect signal from the cancer cells, 
the animals were injected with 100ul 15mg/ml luciferin substrate via subcutaneous 
injection at the neck of luciferin solution. 7-8 minutes after injection the animals were 
anesthetized by gas anesthesia using 2% isoflurane and 1L/min O2. At 15 minutes after 
injection one animal was placed into the IVIS and bioluminescent counts were taken. 
Images were taken when the animal was supine, supine with the abdomen covered, prone, 
and left and right sides. Animals were imaged twice a week throughout the course of 
treatment. As formation of spontaneous metastases occurred luminescent counts become 
visible in the chest region  due to pulmonary metastasis. The experimental groups were 
given treatments in the forms of 120ug/ml for ellagic acid (EA) in the drinking water. We 
used ALZET mini-osmotic pumps (DURECT Corporation, Cupertino, CA) for 
administering endostatin and MRS2179 (Sigma). The pumps deliver 0.11ul/hr and hold up 
to 100ul of liquid for the course of 28 days. Endostatin was delivered at 20mg/kg/day, 
while MRS2179 was at 12.5ug/kg/day. Units are mg of drug/mass of animal/day. A 
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combination treatment group of MRS2179 and EA was also included. After the full course 
of treatment the animals were euthanized and the lungs, liver, and kidneys were collected. 
Each organ set was placed into a 10cm round culture dish, washed with 1X sterile PBS, 
and covered with 15mg/ml luciferin solution. Organ sets were imaged with the IVIS to 
visualize and quantify metastatic tumor growth. Image acquisition and analysis of tumors 
was performed through Living Image software. Tumor images were quantified and 
bioluminescence was reported as flux in photons/second. 
 
Obtaining pure NDPK-A and NDPK-B protein 
I. NDPK Plasmid Vector Design 
Nucleotide sequences of Homo sapien NDPK-A and NDPK-B were collected from NCBI. 
Forward and reverse primers for NDPK-A were designed with sequences of 
AAAGAATTCATGGCCAACTGA and AGTCTCGAGTCATTCATAGATCCAG, 
respectively. Forward and reverse primers for NDPK-B were designed as 
AAAGAATTCATGGCCAACCTGGAG and AGTCTCGAGTTATTCATAGACCCAG, 
respectively. A pTXB1 vector model was used (received from Dr. Dean Burkin’s Lab). In 
order to generate a large stock of pTXB1 vector the plasmids were transformed into 
competent DH5α cells.  1ug of plasmid was added to 50ul of cells and put on ice for 30 
minutes. As a positive control, 2.5ul of pUC19 plasmid was added to 50ul of cells and put 
on ice for 30 minutes. Tubes were heat-shocked at 42C for 20 seconds and placed back 
on ice for 2 minutes. 950ul of LB (Luria-Bertani) media was added to each tube and 
incubated for an hour at 37C with 250rpm shaking. 200ul of cells were spread onto pre-
warmed LB plate (ampicillin 100ug/ml) and incubated overnight at 37C. After the 
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overnight incubation, a single colony was picked, added to 2ml of LB (ampicillin 1ug/ml) 
media, and incubated for 5 hours. The cells were transferred into 200ml of LB (ampicillin 
1ug/ml) media overnight at 37C with 250rpm shaking. At an OD of 1.5, according to 
manufacturer’s procedures a High Speed Maxiprep (QIAGEN) was performed on the 
pTXB1/DH5α cells to collect the pTXB1 plasmid. All DNA and RNA concentrations were 
determined via Nanodrop spectrophotometer. cDNA was synthesized with RNA extracted 
from MDA-MB-231 cells using a MagMAX-96 Total Isolation kit (Life Technologies). 
PCR was used for performed to generate NDPK-A and NDPK-B transcripts flanked with 
EcoRI and XhoI cut sites for cloning. Contents of PCR for NDPK-A and NDPK-B were 
44ul SuperMix High Fidelity (Invitrogen), 2ul 10mM forward primers, 2ul 10mM reverse 
primers, and 180ng cDNA. Program for PCR was an initial melt at 94C for 3 min, 80C 
hold for the addition of Taq, 94C for 45 seconds, 58 for 45 seconds, 72C for 2 minutes 
(35 cycles), and a final 10 minutes at 72C. The samples were held at 4C. Expected size 
for NDPK-A was 477bp and 459bp for NDPK-B. Product presence was confirmed on a 
1% agarose gel run at 110V for one hour. To prepare the NDPK-A and B PCR product and 
pTXB1 plasmid for ligation, an EcoRI and XhoI digestion was performed at 37C for 4 
hours.  To test for digested products, a 1% agarose gel was run at 110V for one hour. Next, 
a ligation was performed using a 3:1 and 4.5:1 ratio of insert:vector for NDPK-A and 
NDPK-B. A combination of 100ng vector DNA, 1ul 10x ligase buffer, 1ul T4 DNA ligase 
and 7ul of DNA insert in nuclease-free water was incubated at 4C overnight. 5ul of the 
ligated plasmid was added to 50ul of competent DH5α cells and incubated on ice for 30 
minutes. Cells were heat shocked at 42C for 20 seconds then placed on ice for 2 minutes. 
950ul of LB medium was added and incubated for 1 hour at 37C with 250rpm shaking. 
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200ul was spread onto LB (1mg/ml ampicillin) plates and incubated overnight at 37C. 18 
colonies from each of the two NDPK-A and two NDPK-B plates were selected and 
inoculated into 5ml of LB (1mg/ml ampicillin). Cells were incubated for 12 hours at 37C 
with 250rpm shaking. Positive colonies with proper insertion of NDPK into the vector were 
confirmed with a 1% agarose gel was run at 110V for one hour. Once identified by agarose 
gel, positive colonies were sent to the Nevada Genomics Center for gene sequence 
confirmation. Once confirmed, our NDPK was transformed into Rosetta E. coli cells for 
IPTG induction and protein purification.  
II. IPTG Induction and Optimization 
One colony of NDPK Rosetta cells was added to 10ml of Terrific broth (TB) media and 
incubated at 30 for 2 hours with 250rpm shaking. At 2 hours, 1 ml of TB was taken out 
and the OD was measured. Cells were allowed to incubate for another 2 hours at 37C. At 
4 hours 1 ml of TB was taken out and the OD was measured. Cells were incubated at 37C 
without shaking for 4 hours, then left to incubate overnight at 37C with 250rpm shaking. 
A growth curve was calculated in order to observe the time course of Rosetta cell growth. 
Once the time and condition was optimized for Rosetta cells to reach an OD of 0.5, IPTG 
was added until a final concentration of 0.5mM was reached. Recombinant NDPK from 
the optimized IPTG induction was confirmed via Coomassie stain and Western blot. 
AVIVA NME1 rabbit primary antibody and anti-rabbit 680 were used for detection of 
NDPK-A, and CPTC NME2-1 mouse and anti-mouse 680 for NDPK-B. To test the most 
efficient method for extraction of intracellular protein from E. coli cells, four different 
conditions were tested: sonication, bullet blending, water bath sonication, and freeze 
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thawing. Extraction buffers used were lysis buffer (LB), LB with EDTA, LB with Triton-
X, LB with lysozyme, and LB with EDTA, Triton-X, and lysozyme.  
 III. Protein Purification  
E. coli cell lysates were prepared for use on a size exclusion column (SEC). Pelleted E. 
coli cells were resuspended with 1ml of room air Kreb’s (RAK) buffer for every 10ml of 
cells pelleted. Cells were sonicated at 5 second pulses and 40% duty cycle with the microtip 
limit at 4. Sonication was performed on ice three times, each time with three bursts. Cell 
debris was pelleted via centrifugation at 15,000rcf for 10 minutes. Supernatant was 
collected and run on size exclusion column. The SEC was packed with P-30 Biorad SEC 
beads. Degassed 1X PBS was used to wash and acclimate the column. Beads were hydrated 
in 1X PBS were slowly poured into the column while avoiding formation of air bubbles. 
Once column was packed, it was washed with degassed 1X PBS. 1ml of E. coli cell lysate 
was added to the column. 1X PBS was slowly added to push sample through SEC. Timer 
was used to measure SEC flow rate and note collection times for 0.5ml fractions to a total 
volume of 50ml. After fraction collection, column was washed with 1X PBS. Protein 
concentration of each 0.5ml fraction was measured using a Nanovue nanodrop 
spectrophotometer set to the Protein 260 function. A spectrograph of each high 
concentration fraction was taken and a graph of fraction concentrations was created to 
determine at which elution times proteins were eluted.   
 
Fractions containing NDPK were further purified using affinity chromatography with an 
ADP column. ADP agarose beads were hydrated with ddH2O overnight at 4C. 1ml of 
beads were packed into a column and the column was washed three times with RAK buffer. 
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Pooled NDPK fractions from the size-exclusion column were added onto the ADP column. 
After samples had run through the column, the column was again washed with RAK buffer.  
NDPK was eluted with approximately 10ml of RAK with 15mM ADP. The sample 
collected was placed in a dialysis bag to exchange the RAK ADP buffer to 1X PBS. 20ml 
of RAK buffer with 10mM ATP was run through the column as a control step in case the 
NDPK did not elute with the addition of ADP. All elution samples were saved and a 0.5ml 
sample was later run on a protein Coomassie gel. ADP agarose beads were washed and 
added to ddH2O with sodium azide for storage at 4C. The levels of purified NDPK-A and 
NDPK-B protein produced from the extractions were tested via Western Blot. AVIVA 
NME1 rabbit primary antibody and anti-rabbit 680 were used for detection of NDPK-A, 
and CPTC NME2-1 mouse and anti-mouse 680 for NDPK-B.  Luminescence activity of 
the protein isolated by each technique was tested via optimized activity assay.  
 
Effect of hypoxia on MDA-MB-231 cells in 2D and 3D cell culture 
I. Cell Culture 
MDA-MB 231 cell line was used. Cells were plated at 4x104 cells/cm2. Conditions were 
two-dimensional (2D) and three-dimensional (3D). The 2D condition cells were plated in 
10 cm round culture dish with DMEM media only. 3D condition cells were plated in 
Engelbreth-Holm-Swarm (EHS) extracellular matrix (BD Biosciences) gel in 10 cm round 
culture dish with DMEM media utilizing the “3D on-top” plating method [8]. Pre-chilled 
culture dished were coated with a thin layer of EHS and incubated for 20 minutes at 37C. 
Appropriate number of cells were suspended in DMEM media and added to the EHS coated 
dishes. Cells were allowed to settle for 20 minutes at 37C. A mixture of 1:9 DMEM:EHS 
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was added to the top of the cells. To determine effects of growth conditions on cell 
morphology and growth patterns, two plates of each 2D and 3D cultures were grown at 
37C, and images of the cells were taken every day for the course of four days.  
II. Hypoxic and normal conditions 
To test the effects of hypoxic conditions on protein production of 231 cells, duplicate 2D 
and 3D cultures were incubated at 37C in a normal 21% O2 condition and a hypoxic 5% 
O2 condition [9]. After a preliminary 24 hour growth period at normal O2 cultures were 
placed in either normal or low O2. At times 0, 1, 3, 6, 12, and 24 hour timepoints the 
cultures from each condition were removed, imaged (Nikon Eclipse TS100 microscope 
with SPOT RT3 camera), and DMEM media was replaced with sterile RAK (room air 
Kreb’s) buffer and replaced to incubate at 37°C for 90 minutes. RAK buffer was collected, 
and cells were isolated for cell lysate preparation. Cells were removed from the bottom of 
their culture flask using 0.05% trypsin and pelleted using a tabletop centrifuge at 1000rpm 
for 10 minutes. 1ml RIPA lysis buffer and 1ul protease inhibitor were added to the cells 
and vortexed for 1 minute. Four alternating cycles of 5 minutes of bullet blending and 1 
minute of vortexing were used to complete the cell lysate. Lysates were stored at -80°C. 
RAK buffer portions were concentrated using centrifugal filters (Millipore Amicon Ultra-
4 Centrifugal Filter Units) and stored at -80°C.  
 
Optimization of an NDPK activity assay 
In order for the assay to be reliable, a reproducible standard curve needed to be created. 
The assay was run in white polystyrene 96-well plates (Sigma-Aldrich #CLS3912) and 
read with a Chameleon plate reader. Previously isolated pure NDPK protein (described in 
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the pure NDPK-A and B protein section) was used. In order to stop enzymatic ATP 
production at determined times, the assay implemented an acid quench followed by a base 
neutralization step for the luciferase reaction. Varying concentrations of HCl and HClO4 
were tested with varying concentrations of NaOH until the resulting pH was between 7.4 
and 8.0. It was found that the most effective and consistent quenching method was with 
buffered forms of acid and base. The most effective combination was the addition of 1:1 
pH 1 RAK buffer with HCl and pH 13 RAK buffer with NaOH. To determine the activity 
of NDPK over time in the presence of its substrate, a 30ng/ml sample of isolated protein 
was added in triplicate to a plate. Substrates were added at 20, 15, 10, 8, 7, 6, 5, 4, 3, 2, 1, 
and 0.5 minutes. After quenching and plotting the curve data it was determined that the 
linear range needed was between 5 and 15 minutes. A 10 minute incubation was used at 
the standard time because it fell within the linear range. To test for differences in maximal 
activity of NDPK, 100ng/ml isolated NDPK samples were incubated and acid-quenched at 
times from 1 to 10 minutes. Activity readings were measured after the acid was added. 
Lysis buffer background luminescence was tested to ensure that the buffer used had the 
least effect on activity readings. The buffers tested were lysis buffer (LB), LB with EDTA, 
LB with Triton-X, LB with lysozyme, and LB with EDTA, Triton-X, and lysozyme. 
Normal concentrations and 1:100 dilutions were tested. Readings of the buffers were 
compared with the background of the plate. After completing the lysis buffer optimization, 
the same four buffer combinations were tested with pure 100ng/ml NDPK dilutions of 1:1, 




Background of various potential substrates and were tested using the activity assay. 
Substrate samples tested were ADP Na+ salt, ADP K+ salt, ADP+GTP, ATP, GTP, UTP 
tris salt, UTP trisodium salt, and CTP salt. Concentrations of substrates were 100uM, 
30uM, 10uM, 1uM, and 0uM.  The ADP+GTP substrate combination was tested in v/v 
ratios of 1:1, 1:2, and 1:10.  
 
Assaying in-vitro secreted protein 
Once the standard curve was optimized and reproducible, secreted proteins collected from 
mammary epithelial cells were used as samples. Due to endogenous components of 
secreted culture samples and blood serum, we expected to have results that were not 
entirely consistent with pure NDPK-A and NDPK-B protein samples. RAK buffer samples 
collected during previous 2D and 3D cell culture experiments were tested. 10ul of sample 
was added in triplicate into a white polystyrene 96-well plate (Sigma-Aldrich #CLS3912). 
A standard curve was plated with triplicate wells of 1000, 300, 100, 30, 10, 3, 1 and 0 ng/ml 
NDPK-B. An ATP standard curve of 100, 10, 1, 0.1 and 0 M ATP was also used. 10ul of 
ADP/UTP (100:300M) substrates were simultaneously added to each sample, the plate 
was shaken for 30 seconds and allowed to incubate at room temperature for 10 minutes. At 
the end of 10 minutes, 5ul of pH 1 RAK was simultaneously added to all wells, the plate 
was shaken for 30 seconds then 5ul of pH 13 RAK was added and the plate was shaken for 
30 seconds to neutralize the acidic pH and prepare the samples for the addition of luciferin-
luciferase reagent. The reagent was prepared by adding luciferin and luciferase enzyme for 
a final concentration of 0.3mM and 3,000 units respectively into Firefly diluent (containing 
98mM Glycine, 2mM Tris base, 10mM MgSO4, 1.1mM EDTA, 2% BSA, and 2% sodium 
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azide). 30ul of Firefly reagent was added mechanically by a Chameleon plate reader and 
luminescence counts were taken for each well. Outliers in luminescence data were removed 
































Previous work completed in the Buxton Laboratory has demonstrated that secreted levels 
of NDPK are increased in tumorigenic and metastatic breast cancer cell lines, but are 
secreted at extremely low levels in non-tumorigenic lines, as seen in the graph in Figure 1 
and the Western Blot in Figure 2. The proposed mechanism for angiogenesis activation, 
cell intravasion and extravasion due to NDPK is illustrated in Figure 3 [10]. Figures from 
A role for nucleotides in support of breast cancer angiogenesis: heterologous receptor 
signaling. N Yokdang, J D Tellez, H Tian, J Norvell, S H Barsky, M Valencik and I L 
O Buxton. Br J Cancer. 2011 10;104(10):1628-40. Epub 2011 Apr 19. 
 






Figure 2. Western blot of secreted 
NDPK-A and NDPK-B from breast 
cancer cell lines and non-tumorigenic                                                                              
cell line, MCF-12. 
 
Figure 1. Comparison of NDPK-B 
secretion from breast cancer cell lines and 







Drug treatment effects on in-vivo tumor growth 
 
To test the hypothesis that NDPK protein is a component of breast cancer tumor growth 
and metastasis, an in-vivo mouse model was used. Mice were individually imaged using 
the IVIS camera and Living Image software. A representative set of images is shown in 
Figure 4. The breast cancer cell line injected into the mouse mammary fat pad is tagged 
with a luciferase gene that emits luminescence after the injection of luciferin. The size and 
spread of the tumors can therefore be visualized with color images. Red indicates regions 
of high intensity and blue indicated regions of lower intensity. Metastatic sites can be seen 
in the lungs. Levels of flux are lower in all experimental groups when compared to the 
control. Differences in tumor growth varied among animals depending on the type of 
treatment administered. Figure 5a shows the total flux data collected from the IVIS camera 
which correlates to the growth rate of the primary tumors over time. Treatments were 
Figure 3. Mechanism of NDPK in promoting 
angiogenesis and metastasis of a primary tumor. 
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started on day 7 which is when the flux data begin to deviate from each other. The figure 
also shows the growth rate of tumors at metastatic sites in the chest region, again using 
IVIS flux data to record changes (Figure 5b). The graph in Figure 6 is a representative 
timepoint of the metastatic growth at the * in figure 5. It can be seen that as compared to 
the control, there were statistically significant reductions in metastasis.  
 
 
Figure 4. IVIS images of late-stage primary tumors and their metastases for the control 










Figure 5. Bioluminescence of cancer cell growth over time for IVIS images in mouse 
models and their respective experimental groups. 5a is primary tumor flux, and 5b is 
metastatic site flux. Ellagic acid (EA) is a NDPK inhibitor, MRS 2179 is a P2Y1 receptor 
antagonist, and endostatin is an endogenous inhibitor of angiogenesis and tumor growth. 
The combination group is EA and MRS 2179. *p<0.05. 
 
 
Figure 6. Comparison of total bioluminescence readings from the control vs. experimental 
treatment groups which shows the reduction in metastasis across all treatment groups.  
 
 
Obtaining pure NDPK-A and NDPK-B protein 
We first needed to create an E. coli cell line that could produce recombinant human NDPK. 
Our subcloning procedure is illustrated in Figure 7. Amplified PCR products were run on 
a gel along with the purified empty plasmid. The resulting gel displays the isolated NDPK-
A and NDPK-B protein PCR products (Figure 8). To check that the PCR products were 
present and the proper digestion occurred, XhoI and EcoRI digested NDPK-A, NDPK-B, 
and pTXB1 plasmid were run on an agarose gel. Resulting bands were all at their expected 
molecular weights and all digestions were clear and in high concentrations (Figure 9). After 
colonies containing pTXB1 plasmids expressing our protein of interest were chosen, they 
were run on agarose gels to detect for the presence of NDPK-A and B. Figure 10 shows 
the results of the gel and the positive colonies, as well as the plates from which colonies 
were selected. IPTG induction was implemented using confirmed positive colonies so that 
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the concentration of cells expressing our protein of interest would increase. In the Western 
blot and Coomassie stain in Figure 11, the increased concentration of NDPK both before 
and after induction is shown, confirming that the induction did indeed allow for the 
production of more protein. Purification of proteins began by testing for the most effective 
method for protein extraction. The Western blot in Figure 12 shows which method yielded 
the most protein, and the activity assay in Figure 13 confirms the Western blot’s results. 
Sonication was shown to be the most effective method for lysing cells. Cell lysate 
supernatant was run on a size exclusion column to isolate our protein of interest. Results 
from the SEC fractions after being read on a nanodrop spectrophotometer are shown in 
Figure 14. Fractions 25-52 and 17-40 were chosen for NDPK-A and B, respectively for 
ADP agarose column purification. Coomassie gels showing the purified NDPK-A and B 




Figure 7. Illustration of order of methods for extraction, ligation, induction and purification 
of NDPK-A and NDPK-B protein. 
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Figure 10. Agarose gels of digested colonies and bands positive for NDPK-A (8a) and 
NDPK-B (8b). For 8a lane: (1) NDPK-A (2) MW ladder (3-20) selected colonies. NDPK-
A is present in lane 12. For 8b lane (1) uncut plasmid (2) digested plasmid (3) NDPK-B 
(4) MW ladder (5-15) selected colonies. NDPK-B is present in all colony lanes. Rosetta 
cell plates from which colonies were chosen are pictured beneath their respective gels. 
 
Figure 8. Agarose gel showing isolated 
NDPK-A and NDPK-B PCR products in 
lanes 2 and 3. 
 
Figure 9. Lane: (1) low MW ladder (2) 
NDPK-A digest (3) NDPK-B digest (4) 






Figure 11. Western blot and Coomassie stain of NDPK-A and B protein from un-induced 
(U) and induced (In) Rosetta cells. Protein concentration increased after induction.  
 
 











Figure 12: Western blot of NDPK-B after 
protein extraction treatments of sonication 
(s) bullet blending (BB) water bath 
sonication (WBS) and freeze thawing (FT). 
A non-induced sample (NI) was included as 
a control.  
 
 
Figure 13. Activity assay results after 
NDPK-B protein extraction treatments 
of sonication, bullet blending, and 
freeze thawing. A non-induced sample 
was included as a control to 
demonstrate that protein levels are 




Figure 14: Nanodrop spectrophotometer readings of protein concentration for each 0.5ml 
fraction of NDPK-A cell lysate after being run through the SEC column. Fractions with 
highest concentrations were combined and run through the ADP column to isolate NDPK 




     
 
Figure 15: Purified NDPK-A and NDPK-B protein are shown on Coomassie gels by the 
presence of a single band. For the gel in 15a containing NDPK-A SEC column products, 
lanes are (1) non-induced (2) IPTG cell lysate (3) flow through (4) washes (5) ADP eluted 
(6) ATP eluted (7) concentrated NDPK-A. For the  gel in 15b containing NDPK-B SEC 
column products, lanes are (1) concentrated NDPK-B (2) ATP eluted (3) ADP eluted (4) 






1         2         3          4          5        6       7      8       9  
MW 17 MW 19 
a.                                                                   b.  
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Effect of hypoxia on MDA-MB-231 cells in 2D and 3D cell culture 
Two-dimensional culture is the traditional method of cell culture where cells are plated 
alone in a plastic dish with liquid media. Three-dimensional cell culture has an additional 
component of a gel-matrix in which cells could grow in-vitro in an environment more 
similar to in-vivo. An illustration of the 3D plating method and protein collection is given 
in Figure 16. A difference in morphology of the cells was observed across different culture 
methods. 2D cells tended to spread out and lie flat across the bottom of their dishes while 
the 3D cells formed more spherical and aggregated shapes as can be seen in the images in 
Figure 17. To test the effects of hypoxic conditions on protein production of 231 cells, 
duplicate 2D and 3D cultures were incubated in a normal 21% O2 condition and a hypoxic 
5% O2 condition [9]. After the proteins secreted in RAK buffer were collected and 
concentrated from the culture grown in either normal or hypoxic conditions an EZQ assay 
was used to determine levels of secreted proteins. The level of secreted proteins was 
significantly higher in the 3D cultures than the 2D cultures in both environmental 
conditions. A general trend was observed that the level of proteins secreted increased over 
the first six hours of treatment and would then decline. The graphs in Figure 18 show levels 
of total secreted protein for all four treatment groups. With the exception of hour 3 samples, 
secretion was higher under hypoxic conditions than normal O2 conditions, which is 
expected from cancer cell lines. Relative levels of intracellular NDPK B collected from 
cell lysate samples made post-RAK collection were measured via Western blot normalized 
to GAPDH expression (Figure 19). Intracellular NDPK protein levels after normalization 
to GAPDH are shown in in Figure 20. These results showed that more NDPK was being 
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produced within the cell under hypoxic conditions than normal conditions, which was what 
would be expected of a cancer cell line. 
 








Figure 18. Total concentration of secreted proteins over time from RAK buffer for each 
treatment group. 18a includes all four treatment group data together, with 18b being normal 
O2 condition data only. 
Figure 16. Illustration of 3D cell culture 
plating and collection of secreted protein. 
Figure 17. Images of 2D and 3D cell 
cultures at increasing magnifications 
showing morphological variations. 
a.  b.  
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Optimization of an NDPK activity assay 
In order to create the least amount of background luminescence, the activity of various 
substrates were tested. From the results in Figure 21, it can be seen that UTP tris emitted a 
signal only slightly higher than the water control, and so optimization continued with the 
use of ADP and UTP standards. Figures 22 and 23 show the optimization of the ATP 
standard curve which is used in conjunction with the NDPK standard curve as a control 
measure. The ATP curve was tested first with an acid quench and base neutralization step 
to create a linear relationship within the curve. It was also determined that the second 
luminescence count reading provided by the Chameleon plate reader was not accurate, and 
only the first reading needed to be recorded. An example of the final optimized ATP curve 
is shown in Figure 23. To confirm the activity of our isolated NDPK-A and B samples, a 
standard curve was created for both isoforms of the protein, seen in Figure 24. Slight 
differences in functionality were expected from the isoforms, and this result was seen in 
the standard curves produced. Another optimization necessary for the assay was the time 
at which the NDPK and substrates should be acid quenched to cease ATP production. A 
Figure 19. Western blot of intracellular 
NDPK collected via cell lysate and 
normalized to GAPDH.  
Figure 20. Results of cell lysates from 
Figure 19 after normalization. NDPK 












time course for both NDPK-A and B was run, and it was determined that the optimal 
reaction time was between 5 and 15 minutes – or within the linear range (Figure 25). The 
final running time was set within this rage at 10 minutes.  Figure 26 is a representative 
example of the final optimization of the NDPK-A and B standard curves which serve as 
the basis for the activity assay as a whole.  These curves have been consistent and 




Figure 21. Test for background luminescence of potential assay substrates. Water was the 







Figure 22. Linearization of ATP 
standard curve via acid quench. Second 
Chameleon reading was confirmed as 
inaccurate for use. 
Figure 23. Representative example of a 
final optimized ATP standard curve for 





Figure 24. Standard curves comparing the relative activity levels of the isolated NDPK-A 




Figure 25. Time courses for isolated NDPK-A and NDPK-B to determine optimal time for 


















































































Assaying in-vitro secreted protein 
Once a consistent and reproducible method for generating an NDPK standard curve was 
accomplished, we could begin testing of RAK buffer samples collected from in-vitro cell 
cultures for NDPK. Preliminary results have shown that the assay can detect varying levels 
of NDPK protein from the buffer samples, and that there are higher levels from  cancerous 
cell lines than for the non-tumorigenic control line (Figure 27). 














Figure 27. Activity assay to test for NDPK activity in in-vitro RAK buffer samples. 
MCF12 is a non-tumorigenic control cell line and shows the lowest activity as compared 






















The activity assay proposed here began on the basis of previous research detailing the 
function of NDPK and its elevated levels within the serum of murine models displaying a 
primary mammary tumor and its subsequent metastatic tumors [10,11]. Without this 
knowledge, the potential of detection of NDPK would not be of use in the medical field. 
The combination of a newly developed detection technique and a recently discovered 
potential cancer biomarker makes for a biomedical research topic with much potential. 
 
The transphosphorylation activity of NDPK is suspected to aid in breast cancer tumor 
metastasis and survival, and its potential target for use as a breast cancer biomarker is very 
intriguing. Through the research performed, an attempt was made to take a pre-existing 
quantification assay technique (luciferin-luciferase activity assay) and optimize it for use 
in the detection of our protein of interest [12]. The creation of non-tagged, functional forms 
of NDPK-A and B isoforms allowed for a proper physiological model to work with. It has 
been shown that the assay can be optimized for use in the accurate detection of ATP 
produced by NDPK over a broad range of protein concentrations. The use of proper timing, 
optimal pH acid quench and base neutralization steps, and incorporation of high 
function/low background substrates allowed for systematic assay accuracy.  
 
While much progress was made on creating a detection method for NDPK, the assay 
optimization process is not yet complete, seeing as only purified protein isoforms have so 
far been used. The preliminary results of in-vitro secreted NDPK proteins from 
concentrated RAK buffer do follow the trend which was to be expected, which is promising 
28 
 
for moving forward with assay samples. Because serum is full of endogenous proteins other 
than NDPK, some of which also produce ATP, future testing will pose other obstacle which 
will require experimentation to eliminate. Currently, the main target for further 
optimization research is adenylate kinase [13]. Background signal from this protein needs 
to be characterized for both murine and human serum samples so that the luminescent 
signal which it creates can be accounted for and subtracted. After that, the assay can be 
used to detect NDPK levels within serum to determine baseline NDPK concentrations in 
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